SCHEMBL10085587

SCHEMBL10085587

CCOCCn1c(=O)[nH]c2ccc(C)cc2c1=O

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
DDR1 Q08345 1/20 0.44
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 3/20 0.44
HPGD P15428 2/20 0.44
HTT P42858 2/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
PKM P14618 1/20 0.44
KMT2A Q03164 1/20 0.44
POLB P06746 2/20 0.43
CYP1A2 P05177 1/20 0.43
TP53 P04637 1/20 0.43
TSHR P16473 1/20 0.43
MAPT P10636 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10085576 0.86 ALDH1A1 (0.57) HSD17B10SMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL10084476 0.85 ADORA3 (0.49) HSD17B10SMN1; SMN2DDR1ALDH1A1KDM4E
SCHEMBL434989 0.82 CYP1A2 (0.64) HSD17B10SMN1; SMN2DDR1ALDH1A1KDM4E
SCHEMBL8987676 0.81 POLB (0.47) HSD17B10DDR1ALDH1A1KDM4EHPGD
SCHEMBL10086066 0.81 ALDH1A1 (0.54) HSD17B10DDR1ALDH1A1KDM4EHPGD
SCHEMBL11014592 0.81 ALDH1A1 (0.47) DDR1ALDH1A1KDM4EHPGDGLA
SCHEMBL8987717 0.80 POLB (0.51) HSD17B10ALDH1A1KDM4EHPGDPOLB
SCHEMBL8987737 0.78 ALDH1A1 (0.66) HSD17B10SMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL10085040 0.78 MPO (0.56) ALDH1A1KDM4EGLAGAAKMT2A
SCHEMBL8987711 0.78 MPO (0.50) HSD17B10ALDH1A1KDM4EHPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 HSD17B10 4071/4885SMN1; SMN2 3062/4885DDR1 4820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.